AVAC Praises CAPRISA 004 Trial Collaborators and Participants for Historic Study - Trial Confirms
"This is a historic day for HIV prevention research. The CAPRISA 004 results are the first clinical evidence that a microbicide gel can help to prevent sexual transmission of HIV infection," said AVAC Executive Director Mitchell Warren, reacting to the results of the landmark microbicide trial presented today at the International AIDS Conference in Vienna. The full AVAC statement is available below.
|AVAC_CAPRISA statement.pdf||23.1 KB|